Sarju Ganatra, Co-Director of the Lahey Innovation Hub at Lahey Hospital and Medical Center, shared a post on LinkedIn about a paper he co-authored with colleagues published in the JACC Journals:
“New CardioOncology American College of Cardiology Concise Clinical Guidance Released!
Honored to share the publication of the 2025 ACC Concise Clinical Guidance on cardiovascular adverse effects of targeted oncology therapies (BTK inhibitors, ICIs, and VEGF inhibitors).
This guidance represents an important milestone for the rapidly expanding cardio-oncology community—providing clear, practical, and point-of-care recommendations for clinicians navigating increasingly complex targeted cancer treatments.
What’s new / What’s inside?
- Practical algorithms
- Case-based learning throughout
- Real-world diagnostic pathways
- Management strategies for:
BTK inhibitors
Immune checkpoint inhibitors
VEGF inhibitors
- A multidisciplinary approach emphasized
- Focus on ‘permissive cardiovascular toxicity.’
- Guidance aligned with everyday clinical decision-making
Why does this matter?
Targeted therapies have transformed cancer care—but they present unique cardiovascular issues that require:
- Early recognition
- Timely evaluation
- Thoughtful management
- Shared oncology–cardiology decision making
The document prioritizes continuity of cancer therapy while preventing avoidable cardiovascular complications.
Grateful to coauthors and collaborators
A very special recognition to Dr. Ana Barac for her exceptional leadership, vision, and guidance in shaping this document and advancing the field of cardio-oncology globally.
Deeply thankful to our outstanding coauthors, writing committee colleagues, and expert contributors.
for their scientific rigor, clinical wisdom, and collaboration throughout this project. This truly reflects collective expertise across cardio-oncology and oncology disciplines.
Gratitude to the ACC Solution Set Oversight Committee led by Gurusher Panjrath, along with peer reviewers Anita Deswal, Diego Sadler, Richard Cheng, Eric EricYang, and ACC leadership for prioritizing this important topic and advancing concise, actionable clinical guidance.
Together, we hope this guidance supports clinicians at the bedside, improves outcomes for patients, and advances our shared mission at the intersection of cardiology and oncology.
Available now in JACC Journals.”
Saro Armenian, Director of the Division of Outcomes Research, Department of Population Sciences, Director of the Center for Survivorship and Outcomes, Hematologic Malignancies Institute, and Barron Hilton Chair and Professor of Pediatrics, Department of Pediatrics at City of Hope, shared this post, adding:
“An important effort for the cardio-oncology community and beyond.”
Title: Diagnosis and Management of Cardiovascular Adverse Effects of Targeted Oncology Therapies: Bruton’s Tyrosine Kinase, Immune Checkpoint, and Vascular Endothelial Growth Factor Inhibitors: 2025 ACC Concise Clinical Guidance
Authors: Sarju Ganatra, Ana Barac, Saro Armenian, Christine Cambareri, Crystal S. Denlinger, Susan F. Dent, Salim Hayek, Bonnie Ky, Monika Leja, Claire Huang Lucas, Bhargav Makwana, Nicolas I. Palaskas, and Jacqueline B. Vo
You can read the Full Article in JACC Journals.
More posts featuring Sarju Ganatra on OncoDaily.